



CORRECTION

Correction to: EPHA2 feedback activation limits the response to PDE δ inhibition in KRAS-dependent cancer cells

Yue-hong Chen^{1,2}, Hao Lv^{2,3}, Ning Shen², Xiao-min Wang^{2,3}, Shuai Tang², Bing Xiong⁴, Jian Ding^{2,3}, Mei-yu Geng^{2,3} and Min Huang^{2,3}✉


Acta Pharmacologica Sinica (2024) 45:1093–1094; <https://doi.org/10.1038/s41401-023-01208-1>

Correction to: *Acta Pharmacologica Sinica* <https://doi.org/10.1038/s41401-019-0268-y>, published online 17 July 2019

The authors are very sorry for two inadvertent mistakes in the figures: the images of immunoblot showing PDE δ expression and the corresponding GAPDH loading control in H1792 and H441 cells in

Fig. 2a were provided incorrectly. These errors were made due to our carelessness during the stage of figure preparation.

The conclusion of the original article or the context of the article was not affected. The corrected figures are presented as follows. The authors deeply apologize for any inconvenience caused to the journal and readers.



¹School of Life Science, Shanghai University, Shanghai 200444, China; ²Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; ³University of Chinese Academy of Sciences, Beijing 100049, China and ⁴Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Correspondence: Min Huang (mhuang@simm.ac.cn)

It should read:




Fig. 2a KRAS mutant cell viability upon PDE δ depletion. KRAS-dependent cells were treated with PDE δ siRNAs (siPDE6D #1, #2) for 96 h. Cell viability was measured by crystal violet staining assay (upper panel). siRNA interference efficiency was measured by immunoblotting (lower panel). The error bars represent the mean \pm SD of four replicates. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$, n.s., not significant.